Comparative Pharmacology
Head-to-head clinical analysis: MUPIROCIN versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUPIROCIN versus SATRIC.
MUPIROCIN vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
No standard dosing information available for SATRIC.
None Documented
None Documented
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category A/B
Category C
Antibiotic
Antiprotozoal, Antibiotic